You can read the full May 17 print issue of Chain Drug Review in its entirety here. In CDR’s digital editions, you can find special sections and additional pages not posted online. You will need to register, but subscription is free!
Our jobs are very different, though we are both pharmacists contributing to the COVID-19 response, and we are proud of the way our profession has stepped up to help. Perhaps it should be no surprise that Americans have turned to pharmacists when deciding whether or not to get a COVID-19 vaccine. According to the National
Americans consistently say congressional action is needed to lower the price of the medicines we need to stay healthy and live productively. In a January 2021 Politico/Harvard T.H. Chan School of Public Health survey, drug prices came second only to COVID-19 relief as the issue we care most about, with 95% of Democrats and 82%
Intellectual property has been essential to the research and development of today’s medicines and will lead to the development and treatment of new medicines addressing still unmet needs. IP is at the core of the health system, as it powers the financing model for R&D. Never has this been more important than today, as the
People involved in the industry commonly refer to the companies at its center as chain pharmacies. The trajectory of the business over the past 15 or 20 years has, however, arguably made the term something of a misnomer. During that period, CVS Health, among others, entered pharmacy benefits management; Walgreens Boots Alliance carved out a
A rethink on the front of pharmacy came about when drug stores took note that people coming in to fill prescriptions had some time on their hands and that time and spending power could be put to great use by offering other items those shoppers might need to pick up. Over the years, this basket
Reports from sources close to Walgreens Boots Alliance to the effect that the company’s talented and personable senior executive Alex Gourlay was, for now at least, preparing for retirement brought a sharper reaction from the chain drug community than so important a transition usually elicits. The response was primarily the natural result of the affection
